ABMT and breast cancer: what have we learned?
The debate regarding the efficacy of and insurance coverage for ABMT for breast cancer has been raging since the widespread dissemination of ABMT in the early 1990s. Underlying the debate was the expectation that the results of randomized clinical trials would finally provide scientific data to resolve the frequently emotional controversy. Unfortunately, the results of these eagerly awaited trials failed to show a significant impact in patients with either metastatic breast cancer or those at high risk for metastatic disease. ABMT, as it is now offered, will not provide the breakthrough that was anticipated or a substantial benefit to the majority of patients. Research on ABMT may have evolved from the initial expectation that the trials would confirm a positive to more modest expectations that trials will disprove a negative. The promising results of early trials still require confirmation through randomized controlled trials, and participation in such clinical trials is vitally important.
Brown
E
E
D016026:Bone Marrow Transplantation / Q000191:economics; D001943:Breast Neoplasms / Q000628:therapy*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D019458:Insurance Coverage; D015588:Observer Variation; D014182:Transplantation, Autologous / Q000191:economics; D016896:Treatment Outcome; D014481:United States